Preneoplastic lesions, detectable by breast cancer screening, are made up of altered cells that are not themselves cancerous but indicate an increased likelihood that a benign or cancerous tumor may subsequently form. In the March 1 issue of the Journal of Clinical Investigation, Federica Cavallo and colleagues from the University of Turin, Italy, evaluated vaccine strategies for treating neoplastic lesions. The authors designed a combined approach consisting of a primary vaccination with plasmids encoding portions of the oncogenic protein rp185neu and a booster vaccination one week later with cells expressing this protein and also engineered to release IFN-gamma. Of mice that received the combined vaccine, 48% remained tumor free for the duration of the study, a significant improvement over untreated mice and mice receiving only the primary vaccine. Both morphologic analysis of the lesions and microarray analysis of gene expression in parallel revealed that the immune reaction halted carcinogenesis and reverted neoplastic lesions to an early stage. This study highlights the potential of a combinatorial approach to vaccination for the prevention and suppression of neoplastic lesions.
TITLE: Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions
AUTHOR CONTACT:
Federica Cavallo
University of Turin, Orbassano, Italy.
Phone: 39 11-670-8119
Fax: 39-11-236-8117
E-mail: federica.cavallo@unito.it
View the PDF of this article at: https://www.the-jci.org/press/19850.pdf
**********************************************
Gene therapy for a broken heart
Despite significant ad-vances in the treatment of cardiac disease, chronic heart failure remains a leading cause of morbidity and mortality. Gene
'"/>
Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
1-Mar-2004